Neurocrine's total assets for Q2 2026 were $5.36B, an increase of 9.23% from the previous quarter. NBIX total liabilities were $1.67B for the fiscal quarter, a 11.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.